…What the agreement actually says about drugs, vaccines, Nigeria’s financial commitment and regulatory oversight — and why Ghana rejected a similar deal
By Debo Adeoye, Ibadan
A five-year health cooperation agreement signed by the governments of Nigeria and the United States has come under renewed scrutiny following claims that Nigeria agreed to accept American vaccines and medicines without allowing the National Agency for Food and Drug Administration and Control (NAFDAC) to test them.
The controversy has intensified following Ghana’s rejection of a similar proposed agreement with Washington over concerns about access to sensitive health data. Critics have consequently questioned whether Nigeria adequately protected its public health interests, data sovereignty and regulatory independence before entering into the arrangement.
However, an examination of the Nigerian Government’s public announcement, the available text of the agreement, NAFDAC’s published regulatory procedures and reports on Ghana’s decision reveals a more complicated picture.
The agreement is real, and Ghana did reject a proposed US health deal. But the claim that Nigeria agreed to accept untested vaccines and drugs because NAFDAC was prohibited from testing them is not established by the available evidence. The financial arrangements have also been misrepresented in some accounts.
The findings raise legitimate questions about transparency, the sharing of health information, the use of public funds and the protection of Nigeria’s regulatory authority. Those concerns deserve investigation without presenting unverified allegations about lethal vaccines or deliberate population control as established facts.
1. What Nigeria actually signed
On December 19, 2025, Nigeria and the United States signed a five-year Memorandum of Understanding (MoU) on health cooperation. The agreement is scheduled to cover the period from April 2026 to December 2030.
According to Nigeria’s Federal Ministry of Health and Social Welfare, the arrangement is intended to strengthen disease surveillance, improve laboratory systems, support healthcare workers, expand access to essential medical commodities and improve primary healthcare delivery.
The diseases and health priorities covered include HIV/AIDS, tuberculosis, malaria, polio, maternal health and child health. The agreement also addresses the collection, transportation, testing, storage and disposal of pathogen samples, alongside improvements to health information systems.
The agreement therefore extends beyond supplying vaccines and medicines. It concerns how Nigeria finances healthcare, monitors infectious diseases, manages laboratory systems and works with the United States on public health programmes.
The distinction matters because claims that the agreement is simply an arrangement for the US to distribute free drugs and vaccines omit substantial parts of its provisions.
2. The $5.1 billion question: Is the US giving Nigeria $3 billion in free drugs?
No. The official figures do not support that description.
The Nigerian Government’s announcement provides the following breakdown:
|Component|Amount|What it represents|
|—|—:|—|
|Planned US contribution|Nearly $2.1 billion|Grant funding for health programmes over five years|
|Nigeria’s domestic health financing commitment|Nearly $3 billion|Projected Nigerian Government spending on health over the same period|
|Combined projected commitment|Approximately $5.1 billion|The two countries’ respective financial commitments|
The US Department of State announced its intention to commit nearly $2.1 billion to Nigeria’s health programmes, subject to the applicable funding arrangements. Nigeria, in turn, committed to increasing domestic health financing, with the government projecting nearly $3 billion in additional or mobilised domestic health spending over the five-year period.
These figures should not be confused with a promise that the United States will supply Nigeria with $3 billion worth of free medicines and vaccines.
Nor does the headline figure mean that the entire $2.1 billion US contribution will arrive as cash paid directly into the Nigerian Treasury. The agreement envisages support across several health programmes, commodities, personnel and health-system activities.
There is also an important distinction between a grant commitment and money already disbursed. The announcement of intended funding does not, by itself, establish how much has actually been released, spent or converted into medicines, vaccines and services.
That requires an examination of subsequent disbursement records, procurement contracts, inventories and implementation reports.
The counterpart-funding issue
Nigeria’s commitment to increase domestic health spending deserves particular attention.
The Ministry of Health said the country committed to allocating at least six per cent of executed annual federal and state budgets to health, with nearly $3 billion in domestic health financing projected over the agreement’s duration.
The public should therefore demand clarification on how the government will calculate this commitment, which existing expenditures will count towards it, and how officials will demonstrate that the promised expenditure represents genuine investment in healthcare.
The key question is not simply whether Nigeria has promised to spend money. It is whether the expenditure will be transparently accounted for and translate into better healthcare for citizens.
3. Did Nigeria agree to stop NAFDAC from testing American vaccines and medicines?
This is the central allegation in the circulating warning.
The investigation found no substantiated evidence in the available agreement text establishing a blanket prohibition on NAFDAC inspecting or testing US-funded vaccines and medicines.
The agreement does, however, contain provisions concerning regulatory reliance.
The text refers to the NAFDAC–US Food and Drug Administration (FDA) mutual recognition framework and Nigeria’s regulatory reliance directives. These provisions are intended to accelerate the evaluation of relevant applications by relying on assessments already conducted under recognised regulatory arrangements.
Regulatory reliance is an established approach in pharmaceutical regulation. Rather than independently repeating every assessment, a national regulator may use another trusted regulator’s work to inform its own decision.
But relying on another regulator’s assessment is not automatically the same as surrendering all domestic regulatory authority.
The critical questions are how the arrangement will be implemented, which products and assessments will qualify, what powers NAFDAC retains, and whether the agency can require additional testing or reject a product when safety, quality or efficacy concerns arise.
The agreement’s provisions should therefore be assessed in their precise legal and operational context rather than reduced to a claim that NAFDAC has been forbidden from testing any American medicine.
What NAFDAC’s own published procedures say
NAFDAC’s published guidance on vaccines describes a regulatory process that includes sampling, document review, risk assessment, laboratory analysis and decisions on whether individual vaccine batches should be released or rejected.
Its Vaccines, Biologicals and Medical Devices Laboratory Services Directorate states that it conducts physical, chemical, microbiological and serological testing of vaccines and other regulated biological products.
The agency also explains that vaccine lot release involves reviewing product documentation and conducting quality-control testing as appropriate before deciding whether a batch meets regulatory requirements.
These published procedures establish NAFDAC’s general regulatory role. They do not, by themselves, resolve every question about how the US–Nigeria agreement might affect particular products.
To settle the controversy conclusively, NAFDAC and the Federal Ministry of Health should publish a clear explanation of how the agreement interacts with the agency’s existing powers.
They should answer five specific questions:
1. Will NAFDAC retain the authority to inspect imported medicines and vaccines supplied under the agreement?
2. Under what circumstances can the agency conduct independent laboratory testing?
3. Can NAFDAC reject a product or batch that fails to meet Nigerian regulatory requirements?
4. Which foreign regulatory assessments will Nigeria rely on, and what safeguards will apply?
5. Will the government publish a list of the products supplied under the arrangement and the regulatory procedures applied to them?
Until these questions are answered with documentary evidence, it would be premature to conclude either that NAFDAC has lost its regulatory powers or that the agreement raises no regulatory concerns.
4. Why did Ghana reject its proposed US health agreement?
Ghana’s rejection is real, but reports identify *health-data protection and sovereignty concerns as central reasons for its decision*, rather than establishing that Ghana rejected the agreement specifically because the US wanted to prevent its regulator from testing vaccines.
On April 28, 2026, Reuters reported that Ghana had declined a proposed bilateral health agreement with the United States after concerns emerged about provisions requiring the sharing of sensitive health data.
Subsequent reporting by The Associated Press quoted Ghana’s Data Protection Commission executive director, Arnold Kavaarpuo, as raising concerns about the scope of access proposed for US entities, including access to health datasets, metadata, dashboards, reporting tools and data models without sufficient prior approval or oversight. Ghana sought better protections.
The proposed arrangement would have provided Ghana with approximately $109 million in US funding over five years, with Ghana expected to make additional domestic investments.
The concerns illustrate the difficult choices facing governments negotiating health partnerships with wealthier countries: how to secure financial and technical assistance while protecting sensitive health information and retaining control over national health systems.
Ghana’s decision is relevant to Nigeria because both countries were negotiating under the Trump administration’s America First Global Health Strategy.
However, the existence of similar negotiations does not prove that the two countries were offered identical agreements or faced precisely the same conditions.
Ghana’s decision is a reason for Nigeria to scrutinise its own agreement carefully, not proof that Nigeria accepted a ban on vaccine testing.
5. What are the real concerns in Nigeria’s agreement?
The absence of substantiated evidence for the alleged blanket testing ban does not mean that the agreement is beyond criticism.
The available text identifies several issues that deserve close examination.
A. Sharing pathogen samples and genetic information
The agreement envisages Nigeria negotiating a specimen-sharing arrangement involving samples and related data, including genetic sequence data, from detected pathogens with epidemic potential.
The text says such sharing would be subject to approval by a data and specimen governance committee on a case-by-case basis. It also envisages a five-year term, renewable by mutual agreement.
This is a significant public-interest issue.
Information about pathogens can help researchers understand infectious diseases, track outbreaks and develop diagnostics, treatments and vaccines. International sharing can therefore provide genuine public-health benefits.
However, questions remain about governance, access, permitted uses, storage, ownership, commercial applications and the extent to which Nigeria will benefit from research and products developed using information or samples originating within its borders.
Nigeria should explain the safeguards that will prevent misuse and ensure that the country and its citizens receive appropriate benefits from the arrangement.
The public should also be able to understand what information may be shared, who may access it and what restrictions apply.
B. Protection of citizens’ medical information
The agreement also raises questions about health-data access and oversight.
Nigeria’s data protection framework and relevant laws must be considered when assessing how personal information is collected, transferred, stored and used.
In March 2026, Premium Times reported that a legal practitioner had filed a suit at the Federal High Court in Abuja challenging aspects of the US–Nigeria health agreement over concerns about the sharing of citizens’ health data, privacy and constitutional compliance. The filing represented allegations before the court, not proof that the agreement had been judicially found unlawful.
The appropriate response is for the government to explain the safeguards, access controls and oversight mechanisms governing any transfer or use of personal health information.
Citizens should not have to rely on rumours to understand how their medical information may be handled.
C. Financial accountability
The US contribution and Nigeria’s domestic spending commitment need to be tracked separately.
The government should publish regular reports showing:
– The amount of US funding committed, released and spent.
– The amount Nigeria has budgeted and actually spent under the agreement.
– The programmes and facilities receiving support.
– The quantities and types of medicines, vaccines and equipment procured.
– The procurement prices, suppliers and applicable quality-assurance procedures.
– The geographical distribution of services and commodities.
– The results achieved, including measurable improvements in treatment access and disease control.
Without this information, citizens cannot independently determine whether the arrangement represents value for money.
D. Distribution and political interference
The suggestion that a disproportionate share of medicines and vaccines will be directed to Nigeria’s South-East region for political purposes has not been substantiated by the available evidence.
The agreement does contain provisions for targeted health interventions, including malaria programmes in selected high-burden areas.
Targeting areas with greater disease burdens can be a legitimate public-health strategy. However, geographical targeting should be supported by published epidemiological evidence and transparent allocation criteria.
The government should therefore disclose how states and local government areas will be selected, how commodities will be distributed and what measures will prevent political patronage or diversion.
Any claim that particular regions will receive supplies for electoral purposes requires documentary evidence, such as allocation records, distribution instructions or credible testimony from officials involved in implementation.
6. Are the vaccines and medicines dangerous because they are supplied by the United States?
The available evidence does not justify that conclusion.
The nationality of a medicine’s supplier does not, by itself, establish whether the medicine is safe or unsafe. Safety depends on the particular product, its quality, evidence of efficacy, manufacturing standards, storage conditions, handling and appropriate use.
Likewise, the fact that a medicine is supplied without charge to a patient does not establish that it is dangerous.
The appropriate safeguards are independent regulatory oversight, quality assurance, reliable supply chains, monitoring of adverse reactions and transparent communication with patients.
NAFDAC’s published procedures recognise the importance of product documentation, risk assessment, laboratory analysis where appropriate and batch-release decisions.
Before any particular vaccine or medicine is administered, Nigerians should be able to establish:
– Its name, manufacturer and intended use.
– Whether it has the required authorisation for use in Nigeria.
– Whether the relevant batch has met applicable quality requirements.
– The recommended dosage, contraindications and known side effects.
– The arrangements for reporting and investigating adverse reactions.
These are reasonable questions for patients, journalists, health professionals and public authorities to ask.
However, there is no substantiated evidence in the material examined for this investigation that the agreement is a plan to reduce Nigeria’s population through lethal vaccines or medicines.
Such a serious allegation should not be circulated as fact without credible scientific and documentary evidence.
The responsible approach is to investigate identifiable products and regulatory provisions rather than frighten the public away from medical interventions that may be beneficial.
7. Does the agreement give the United States control over Nigeria’s health system?
The agreement establishes a framework for bilateral cooperation and includes provisions that warrant scrutiny.
Its published text addresses health financing, laboratory systems, disease surveillance, health commodities, data access and specimen sharing. It also includes provisions concerning audits and the possible consequences of failing to fulfil certain commitments.
For example, the text provides for regulated access to information needed for specified audits and states that failure to provide requested information could result in changes to planned assistance or discontinuation of the agreement.
These provisions raise legitimate questions about the balance of obligations between the two governments.
What happens if Nigeria and the United States disagree over data access? How will disputes be resolved? What safeguards protect information that Nigerian law treats as confidential? What happens to ongoing health programmes if US funding is withdrawn?
These questions require answers from the officials who negotiated the agreement.
Nevertheless, the existence of funding conditions and audit provisions does not, on its own, establish that the United States has acquired control of Nigeria’s health system.
A proper assessment requires close examination of the agreement’s language, applicable Nigerian law and its implementation in practice.
8. What should the Nigerian Government disclose?
The controversy has exposed a clear need for accessible public information about the agreement.
Although the Federal Ministry of Health announced the signing and summarised its main objectives, the public needs sufficient detail to assess the legal, financial, regulatory and public-health implications.
The government should publish the complete signed agreement, its implementation schedules, relevant annexes, funding arrangements and any associated specimen-sharing or data-sharing instruments that can lawfully be disclosed.
It should also explain whether the agreement has been amended since signing and identify the agencies responsible for implementing each major commitment.
The National Assembly should exercise its oversight responsibilities where applicable, while NAFDAC should explain the regulatory implications for imported medicines and vaccines.
Civil society organisations, medical associations, public-health researchers and data-protection experts should be able to examine the relevant documents and provide evidence-based assessments.
Transparency would help distinguish legitimate concerns from misinformation and give Nigerians a stronger basis for holding public officials accountable.
9. Questions that remain unanswered
Based on the documents and reports reviewed, the following issues merit further investigation:
First: What precise legal effect does the regulatory reliance provision have on NAFDAC’s authority to assess products supplied under the agreement?
Second: Which medicines and vaccines will be procured, and what product-specific authorisation and quality-assurance requirements will apply?
Third: How much of the announced US funding has actually been released, and how much has Nigeria spent under the domestic financing commitment?
Fourth: What personal health information and pathogen-related data will be shared, with whom, for what purposes and under what safeguards?
Fifth: What arrangements govern the ownership, storage, commercial use and potential downstream benefits of biological samples and genetic information originating in Nigeria?
Sixth: What criteria will determine which states, local government areas, hospitals and patient groups receive the programmes’ benefits?
Seventh: What monitoring and accountability mechanisms will enable Nigerians to identify substandard products, report adverse reactions and seek redress?
These are not peripheral matters. They concern public health, financial accountability, national sovereignty and citizens’ rights.
Conclusion: Nigeria needs answers, not panic
Nigeria’s health agreement with the United States is a documented policy decision with substantial financial and public-health implications.
The United States has announced nearly $2.1 billion in planned grant support, while Nigeria has committed to domestic health financing projected at nearly $3 billion over five years. Ghana, meanwhile, rejected a proposed US health deal amid concerns about sensitive health-data sharing.
The investigation did not establish the claim that Nigeria agreed to a blanket prohibition on NAFDAC testing American medicines and vaccines. Nor did the evidence establish that the arrangement is designed to cause deaths or reduce Nigeria’s population.
That does not remove the need for scrutiny.
The agreement’s provisions on regulatory reliance, specimen sharing, health-data access, domestic financing and accountability deserve careful examination. The government should publish the relevant documents and provide clear answers to the questions raised.
For journalists, the task is to follow the money, examine the documents, verify the regulatory provisions and seek responses from the officials responsible.
For Nigerians, the essential safeguard is access to reliable information about the medicines and vaccines they are offered.
The central issue is not whether a medicine is free or comes from America. It is whether the product is appropriate, meets the required quality and safety standards, is properly regulated, and is supplied through a transparent and accountable system.
Public vigilance is necessary. But vigilance must be grounded in evidence, because misinformation can also put lives at risk.
